Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

/PRNewswire/ -- Pivotal data from the Phase 3 XTEND-Kids study evaluating efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein]...

Related Keywords

Montreal ,Quebec ,Canada ,United States ,Russia ,Australia ,Stockholm ,Sweden ,America ,Lydia Abad Franch ,Drug Administration ,Nasdaq ,Head Of Research Development ,Development Of Factor ,Linkedin ,Meeting Of The International Society On Thrombosis ,Euronext ,Youtube ,European Commission ,European Medicines Agency ,Sobi Investor Relations Team ,Annual Meeting ,International Society ,Medical Affairs ,Chief Medical Officer ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Marketing Authorization Application ,North Africa ,Middle Eastern ,North America ,Middle East ,Sobi Media ,Orphan Biovitrum ,